NMIBC sample collection to test cancer monitoring biomarkers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, multi-center study collects blood, urine, and residual tumor tissue from NMIBC patients during standard care. It aims to evaluate the clinical performance of Natera’s MRD assays for detecting ctDNA to monitor disease status and treatment response. Participants are followed for up to three years, with samples collected for up to two years and data-only follow-up for one year. Two cohorts are enrolled: intravesical/systemic therapy (Cohort A) and cystectomy (Cohort B). No individual test results will be shared with participants or their clinicians. Tissue samples are obtained from standard-of-care procedures and used for research.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patient is at least 18 years of age or older.
2. Eastern Cooperative Oncology Group performance status ≤ 2.
3. Patient has a suspected high risk non-muscle invasive bladder cancer.

   Note: The AUA/SUO risk stratification for primary non-muscle invasive bladder cancer will be used to determine high risk of tumor progression based on clinic and pathologic prognostic factors (Holzbeierlein et al., 2024):
   1. High grade T1.
   2. Any recurrent, High-grade TA.
   3. High grade TA, \>3 cm (or multifocal).
   4. BCG failure in high grade patient.
   5. Any variant histology.\*

      \*e.g. Micropapillary, plasmacytoid, small cell/neuroendocrine, and sarcomatoid histologies (in pure or mixed form with associated urothelial carcinoma)
   6. Any lymphovascular invasion.
   7. Any high grade prostatic urethral invasion.
4. Meet the following criteria:

   a. Cohort A: i. Participant has high risk ≤ T1 bladder cancer and is eligible for intravesical therapy or cystectomy. ii. Participant has been treated with intravesical and/or systemic therapy for high risk ≤ T1 bladder cancer and is entering surveillance. b. Cohort B i. Participant has high risk ≤ T1 bladder cancer and undergoing primary treatment with cystectomy. ii. Patients undergoing cystectomy following recurrence or progression of high risk ≤ T1 bladder cancer and where ≤ T1 bladder cancer is confirmed on cystectomy surgical pathology.
5. Willing and able to tolerate blood draws according to Natera standard process.
6. Willing to provide urine collection samples.
7. Able to consent to and provide residual tumor tissue for research.
8. Willing and able to comply with the study requirements.

Exclusion Criteria:

1. Pregnant or breastfeeding.
2. Prior history and treatment for any cancer (including muscle invasive bladder cancer) within the past year, or if they have any other active cancer, with the exception of participants who have undergone surgical removal of basal or squamous skin cancers, as well as those who have received NMIBC-directed therapy, including those undergoing cystectomy for primary NMIBC or after recurrence/progression of NMIBC.
3. Diagnosis of \>T1 bladder cancer at time of enrollment.
4. Tumor tissue unavailable and/or consists only of carcinoma in situ (CIS) disease.
5. At time of enrollment, has undergone or plans to undergo any ctDNA or utDNA testing to assess MRD, with the exception of one-time comprehensive genomic profiling for therapeutic drug selection.
6. History of bone marrow or organ transplant.
7. Serious medical conditions that may adversely affect ability to participate in the study.

Where it's running

• Natera, Inc.
  Austin, Texas, United States Recruiting

Study contacts

• Study coordinator: SCORE-NMIBC Study team
• Email: contactscorenmibc@natera.com
• Phone: 650-489-9050

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 1-Year Recurrence After En Bloc Resection for Large Bladder Tumors

  This trial tests whether en bloc resection of bladder tumors larger than 2.5 cm can reduce recurrence compared with standard transurethral resection in adults with non-muscle invasive bladder cancer.

  Recruiting Phase 3 Rabin Medical Center · Petah Tikva · NCT07898033

• Feasibility of automatic, laser-based distance control in people with superficial bladder tumors

  This study tests whether the ATLAS system’s distance sensor can accurately guide laser treatment for Ta low-grade bladder tumors in patients during a scheduled outpatient procedure.

  Recruiting Optheras AS · Herlev · NCT07860398

• Sequential Gemcitabine Plus Docetaxel vs Gemcitabine Plus Mitomycin C for BCG-Unresponsive NMIBC

  This study tests whether adding docetaxel after gemcitabine is better or worse than adding mitomycin C after gemcitabine for people with BCG-unresponsive high-grade non-muscle-invasive bladder cancer.

  Recruiting Phase 2 Blokhin's Russian Cancer Research Center · Moscow, Moscow · NCT07747740

• Intravesical UGN-501 for Recurrent NMIBC (Phase 1, dose-escalation)

  This study tests whether UGN-501 can be safely given into the bladder to treat adults with recurrent non-muscle invasive bladder cancer.

  Recruiting at 6 sites Phase 1 UroGen Pharma Ltd. · Queen Creek, Arizona and 14 other locations · NCT07725796

• Is ongoing systemic immunotherapy needed after achieving tumor-free status in very-high-risk NMIBC?

  This study tests whether patients who have become tumor-free after a systemic immunotherapy-based bladder-sparing treatment can safely stop therapy and instead be watched closely.

  Recruiting at 4 sites Phase 2 Tianjin Medical University Second Hospital · Tianjin and 3 other locations · NCT07625527

• Comparing CT and MRI with VI-RADS for Bladder Cancer Staging

  This study tests how well CT and MRI with VI-RADS can correctly stage bladder cancer before surgery in adults.

  Recruiting Oslo University Hospital · Oslo · NCT07602010

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.